Understanding the Disease

Acute Myeloid Leukemia (AML)

AML: The most common leukemia in adults

Being diagnosed with AML can be an overwhelming experience. You may feel like your whole life has been turned upside down. At Novartis, we understand that you’re facing new challenges, but we want you to know that we’re committed to providing you with support.

Understanding AML and how it’s managed is an important first step. The information on this website is meant to help you and those close to you learn more about AML and what you might expect throughout your journey.

You’ll also learn about your treatment with RYDAPT® (midostaurin) capsules and how it may play an essential role in the overall plan that your health care team has created for you.

What is AML?

AML is a type of blood cancer that primarily affects your white blood cells. In AML, the myeloid stem cells usually become a type of immature white blood cell called myeloblasts (or myeloid blasts). The myeloblasts in AML are abnormal and do not become healthy white blood cells.

Leukemia cells often reproduce quickly, but in most cases the problem is that they don’t die when they should. Acute leukemias, like AML, are fast growing because normal blast cells divide quickly. The leukemia cells don’t divide any more often than normal blast cells do. However, they don’t stop dividing when normal blast cells would.

AML is the most common type of acute leukemia affecting adults. About 19,940 new cases of acute myeloid leukemia (AML) per cancer.gov. 

19,940 people in the United States were estimated to have been diagnosed with AML in 2017

US AML Patient Support Groups

There are a number of patient support groups active in the United States. Please click through on the links below to find out more.

Leukemia & Lymphoma Society

CancerCare

PatientPower